The Battle of Delivery Strategies for GPL-1 Peptide
Скачать файл:
URI (для ссылок/цитирований):
https://doi.org/10.1016/j.addr.2018.07.009https://elib.sfu-kras.ru/handle/2311/110992
Автор:
Minzhi, Yu
Benjamin, Mason
Santhanakrishnan, Srinivasan
Ekaterina I. Shishatskaya
Steven P. Schwendeman
Anna, Schwendeman
Коллективный автор:
Институт фундаментальной биологии и биотехнологии
Кафедра медицинской биологии
Дата:
2018-07Журнал:
Advanced Drug Delivery ReviewsКвартиль журнала в Scopus:
Q1Квартиль журнала в Web of Science:
Q1Библиографическое описание:
Minzhi, Yu. The Battle of Delivery Strategies for GPL-1 Peptide [Текст] / Yu Minzhi, Mason Benjamin, Srinivasan Santhanakrishnan, Ekaterina I. Shishatskaya, Steven P. Schwendeman, Schwendeman Anna // Advanced Drug Delivery Reviews. — 2018.Аннотация:
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) belong to
an important therapeutic class for treatment of type 2 diabetes. Six GLP-
1 RAs, each utilizing a unique drug delivery strategy, are now approved
by the Food and Drug Administration (FDA) and additional, novel GLP-1 RAs
are still under development, making for a crowded marketplace and fierce
competition among the manufacturers of these products. As rapid
elimination is a major challenge for clinical application of GLP-1 RAs,
various half-life extension strategies have been successfully employed
including sequential modification, attachment of fatty-acid to peptide,
fusion with human serum albumin, fusion with the fragment crystallizable
(Fc) region of a monoclonal antibody, sustained drug delivery systems,
and PEGylation. In this review, we discuss the scientific rationale of
the various half-life extension strategies used for GLP-1 RA development.
By analyzing and comparing different approved GLP-1 RAs and those in
development, we focus on assessing how half-life extending strategies
impact the pharmacokinetics, pharmacodynamics, safety, patient usability
and ultimately, the commercial success of GLP-1 RA products. We also
anticipate future GLP-1 RA development trends. Since similar drug
delivery strategies are also applied for developing other therapeutic
peptides, we expect this case study of GLP-1 RAs will provide
generalizable concepts for the rational design of therapeutic peptides
products with extended duration of action.